AZD-5423

AZD-5423

AZD-5423

Chemical compound

AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca[1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[2][3][4][5][6]

Quick Facts Identifiers, CAS Number ...

It has completed a phase II clinical trial.[7]

See also

References

  1. [1]
    Hemmerling M, Nilsson S, Edman K, Eirefelt S, Russell W, Hendrickx R, et al. (October 2017). "Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases". Journal of Medicinal Chemistry. 60 (20): 8591–8605. doi:10.1021/acs.jmedchem.7b01215. PMID 28937774.
  2. [2]
    "AZD 5423 - AdisInsight".
  3. [3]
    Drahl C (2013). "Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA".
  4. [4]
    GB2010051905 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
  5. [5]
    SE2009050900 A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
  6. [6]
    SE2009000264 Combination of (a) glucocorticoid receptor modulator and (b) a β2-agonist
  7. [7]
    Clinical trial number NCT01555099 for "Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol" at ClinicalTrials.gov



Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article AZD-5423, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.